医学
胃肠病学
乙型肝炎表面抗原
内科学
HBeAg
肝细胞癌
聚乙二醇干扰素
肝硬化
丙氨酸转氨酶
乙型肝炎
病毒载量
乙型肝炎病毒
免疫学
丙型肝炎病毒
病毒
利巴韦林
作者
Qingqing Zhao,Kehui Liu,Xiaojun Zhu,Lei Yan,Yezhou Ding,Yumin Xu,Shike Lou,Gangde Zhao,Qing Xie,Yueqiu Gao,Shisan Bao,Hui Wang
标识
DOI:10.1016/j.antiviral.2020.104953
摘要
Normal/mildly elevated ALT (<2 × ULN) CHB patients are potentially at risk of progression to cirrhosis and/or hepatocellular carcinoma (HCC). We aimed to assess the outcomes of anti-viral therapy for normal/mild elevation of ALT CHB patients. CHB patients (n = 432) who have had liver biopsied were determined. It was determined that the outcomes of anti-viral therapy in CHB patients with normal/mild elevation of ALT, in response to nucleoside/nucleotide analogues (NAs) (n = 190) and pegylated interferon (PEG-IFN) (n = 30) treatment for up to 72 weeks. Non-anti-viral treated patients were used as control (n = 40). There was about 50% of the CHB patients showed hepatic inflammatory necrosis ≥ G2 and/or fibrosis ≥ S2 among >30-years-old. The rate of undetectable HBV DNA in NAs and PEG-IFN groups was ~50%, ~80% or ~90% at week 24, 48 or 72, respectively. HBeAg clearance rate was lower in NAs treated than that in PEG-IFN group at week 48 (6% vs 20%, P < 0.05). ALT normalization rate was increased by 1.18-fold at week 72. HBsAg decline in HBeAg + patients treated with NAs or PEG-IFN was 0.418 or 1.217 log IU/mL (P < 0.0001) at week 48; whereas HBsAg decline was 0.176 or 0.816 log IU/mL (P < 0.001) in HBeAg − patients. HBsAg at baseline and week 24 were strong predictors of “low HBsAg at week 48”. Long term anti-viral therapy inhibits HBV replication effectively in ALT<2 × ULN CHB patients. PEG-IFN therapy is recommended for HBeAg + patients with baseline HBsAg<4.37 log IU/ml and HBeAg − patients with baseline HBsAg<2.66 log IU/ml to achieve “low HBsAg at week 48”. • CHB patients with persistently normal or slightly elevated ALT (<2 × ULN) may eventually progress into cirrhosis or HCC. • We determined the anti-viral effect (NAs or PEG-IFN) in CHB patients with ALT < 2 × ULN, determined by liver biopsy. • Long term NAs or PEG-IFN inhibits HBV replication effectively in normal/mildly elevated ALT CHB patients. • PEG-IFN is recommended for HBeAg + or HBeAg − patients with baseline HBsAg<4.37logIU/ml or baseline HBsAg<2.66logIU/ml. CHB patients with persistent normal/mildly elevated blood liver function are potentially at risk of progression of liver damage, mainly due to persistent liver damage sub clinically. Anti-viral medication is strongly recommended for these CHB patients to reduce the chance of development of hepatocellular carcinoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI